(Q34953339)

5 August 2017

1 reference

title

Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies (English)

1 reference

5 August 2017

3

Mark Clemons

1 reference

5 August 2017

Andrew Clamp

1

1 reference

PubMed ID

12372723

5 August 2017

Sarah Danson

series ordinal

2

1 reference

5 August 2017

1 October 2002

1 reference

Lancet Oncology Commission

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

611-619

1 reference

5 August 2017

10

1 reference

ABC of breast diseases: breast cancer

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Use of oral contraceptives and risk of breast cancer in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Family history and the risk of breast cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Proportion of breast cancer cases in the United States explained by well-established risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

A prospective study of endogenous estrogens and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Joint effects on cancer risk of age at childbirth, time since birth and attained age: circumventing the problem of collinearity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

BRCA1/2 testing: complex themes in result interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Validation of the Gail et al. model for predicting individual breast cancer risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Breast patterns as an index of risk for developing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

The relation of mammographic features of the breast to breast cancer risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Tamoxifen for breast cancer among hysterectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Clinical effects of raloxifene hydrochloride in women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

LHRH agonists and the prevention of breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Phytoestrogens and breast cancer in postmenopausal women: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Effects of soy phytoestrogens genistein and daidzein on breast cancer growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Breast cancer chemoprevention: beyond tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Breast cancer risk associated with gynecologic surgery and indications for such surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Prophylactic mastectomy--the price of fear.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Women's interest in chemoprevention for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

Uptake of screening and prevention in women at very high risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900875-6

7 January 2021

10.1016/S1470-2045(02)00875-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12372723